Drug policy of the United States

Drug policy of the United States
Unknown authorUnknown author or not provided · Public domain · source
Name	Drug policy of the United States
Caption	Flag of the United States
Jurisdiction	United States
Established	1906
Keylegislation	Harrison Narcotics Tax Act; Controlled Substances Act; Comprehensive Drug Abuse Prevention and Control Act; Anti-Drug Abuse Act
Agencies	Drug Enforcement Administration; Office of National Drug Control Policy; Food and Drug Administration

Drug policy of the United States is the set of laws, regulations, enforcement practices, and public health strategies shaping production, distribution, possession, treatment, and research of psychoactive substances within the United States. It encompasses criminal statutes such as the Controlled Substances Act, administrative actions by the Food and Drug Administration, and political responses by the Office of National Drug Control Policy, tied to international obligations like the Single Convention on Narcotic Drugs and bilateral agreements with Mexico and Canada. Debates over prohibition, regulation, medical use, and harm reduction have involved actors including the Drug Enforcement Administration, state governments such as California, advocacy organizations like the American Civil Liberties Union, and movements such as the War on Drugs.

Historical development

Early regulatory steps included the Pure Food and Drug Act and the Harrison Narcotics Tax Act, shaped by figures like Harry J. Anslinger and institutions including the Federal Bureau of Narcotics and the Treasury Department. Prohibition-era policies intersected with enforcement by the Bureau of Prohibition and motivated later federal consolidation under the Comprehensive Drug Abuse Prevention and Control Act and the Controlled Substances Act during the presidencies of Richard Nixon and Jimmy Carter. The 1980s saw expansion under the Anti-Drug Abuse Act of 1986 and the influence of administrations such as Ronald Reagan and George H. W. Bush, while the 1990s and 2000s featured litigation in courts like the Supreme Court of the United States and policy shifts in states like Oregon and Vermont. Responses to the opioid epidemic involved regulatory action by the Centers for Disease Control and Prevention, reforms inspired by research from the National Institute on Drug Abuse, and state-level initiatives in jurisdictions including Kentucky and West Virginia.

Legal and regulatory framework

Federal statutory architecture centers on the Controlled Substances Act, enforced by the Drug Enforcement Administration and administered through scheduling processes involving the Department of Justice and the Department of Health and Human Services. Regulatory oversight of pharmaceuticals is conducted by the Food and Drug Administration, while public benefits and payment for treatment intersect with policies of the Centers for Medicare & Medicaid Services. International treaty obligations include the Single Convention on Narcotic Drugs and the Convention on Psychotropic Substances, negotiated by the United Nations. State legislatures in Colorado, Washington (state), and Massachusetts have enacted laws conflicting with federal schedules, prompting litigation in circuits such as the U.S. Court of Appeals for the Tenth Circuit and decisions by the U.S. Department of Justice.

Federal agencies and enforcement

Primary enforcement roles are held by the Drug Enforcement Administration, supported by the Federal Bureau of Investigation and the Bureau of Alcohol, Tobacco, Firearms and Explosives in interdiction and prosecution. Public health coordination involves the Centers for Disease Control and Prevention, the Substance Abuse and Mental Health Services Administration, and the National Institutes of Health including the National Institute on Drug Abuse. International interdiction and diplomacy engage the Department of State and the Office of National Drug Control Policy. Local enforcement often involves municipal police departments and state patrols such as the California Highway Patrol, while federal prosecutions are pursued by United States Attorneys in districts across jurisdictions like the Southern District of New York.

Criminal justice and sentencing policy

Mandatory minimums from laws like the Anti-Drug Abuse Act of 1986 shaped sentencing practices adjudicated in cases before the Supreme Court of the United States and sentencing commissions including the United States Sentencing Commission. Disparities highlighted by organizations such as the American Civil Liberties Union and litigation in courts including the U.S. Court of Appeals for the Second Circuit prompted reforms such as the Fair Sentencing Act of 2010. Alternatives include drug courts modeled on programs from Dade County (Florida) and diversion initiatives in states like New York (state) and Pennsylvania. Reentry and pardon processes involve the Department of Justice and gubernatorial actions in states like Illinois and California.

Public health and harm reduction approaches

Harm reduction initiatives include needle exchange programs supported by public health entities like the Centers for Disease Control and Prevention, supervised consumption site proposals debated in cities such as San Francisco and Philadelphia, and medication-assisted treatment using drugs regulated by the Food and Drug Administration such as buprenorphine and methadone. Research funded by the National Institutes of Health and programmatic guidance from the Substance Abuse and Mental Health Services Administration inform interventions deployed by community organizations like the Harm Reduction Coalition. Overdose prevention relies on naloxone distribution supported by nonprofits and state health departments, while federal funding streams involve grants from the Department of Health and Human Services.

Economic and social impacts

Economic effects include enforcement costs measured by the Congressional Budget Office and incarceration expenses managed by the Federal Bureau of Prisons and state corrections systems such as the Texas Department of Criminal Justice. Illicit markets intersect with transnational trafficking through routes involving Mexico and the Caribbean, affecting labor markets in regions like the Appalachian Mountains. Public health burdens include treatment demand reported by the Substance Abuse and Mental Health Services Administration and mortality tracked by the Centers for Disease Control and Prevention. Civil society impacts are highlighted by advocacy from the American Civil Liberties Union, research by universities like Johns Hopkins University and Harvard University, and policy analysis by think tanks including the Brookings Institution and the Cato Institute.

Contemporary debates and reform movements

Current reform movements advocate legalization modeled on statutes in Colorado and Washington (state), decriminalization proposals advanced in Oregon and supported by coalitions such as the Drug Policy Alliance, and rescheduling petitions filed with the Food and Drug Administration and the Department of Justice. Criminal justice reformers leverage reports from the United States Sentencing Commission and litigation in the Supreme Court of the United States to challenge mandatory minimums. Public health advocates cite research from the National Institute on Drug Abuse and pilot programs in cities like Seattle and Baltimore (Maryland) to expand harm reduction. International considerations include treaties overseen by the United Nations Office on Drugs and Crime and bilateral negotiations with governments of Mexico and Canada.

Category:Drug policy